Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Stifel Updates Ests on Biogen (BIIB) Following Q1 Report; Affirms at 'Hold'
April 21, 2016 12:36 PM EDTStifel affirms Biogen (Nasdaq: BIIB) at Hold following Q1 results issued earlier Thursday.
Analyst Thomas Shrader offered the following commentary: Biogen presented 1Q16 financial results today,... More
Biogen (BIIB) CEO Scangos Says Co. in Talks for 'Tuck-in' Deals, Later-Stage Assets - Conf. Call
April 21, 2016 8:55 AM EDTBiogen (NASDAQ: BIIB) CEO Scangos says the company is in talks for 'tuck in' deals and later-stage assets, according to commentary from the company's conference call on Thursday.
... MoreBiogen (BIIB) Tops Q1 EPS by 33c
April 21, 2016 7:16 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $4.79, $0.33 better than the analyst estimate of $4.46. Revenue for the quarter came in at $2.73 billion versus the consensus estimate of $2.75 billion.
Growth was driven by a 15% increase in worldwide TECFIDERA revenues as well as... More
